Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-04-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于公司2018年面向合格投资者公开发行公司债券的更名公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the renaming of a company bond issuance by 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.). It details the approval and issuance of company bonds, the change in the bond's name due to issuance spanning multiple years, and confirms that the legal documents related to the bond issuance remain valid despite the name change. The document is short (1249 characters) and serves as an official announcement about a financing instrument (company bonds). It does not contain financial statements or detailed financial data, nor is it a full report or audit. It is clearly an update related to the company's capital structure and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-04-17 Chinese
2018年面向合格投资者公开发行公司债券（第一期）募集说明书摘要
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus summary for a 2018 corporate bond issuance by 瑞康医药股份有限公司 (Realcan Pharmaceutical Co., Ltd.). It includes extensive information about the bond issuance terms, credit ratings, financial data, risk factors, regulatory approvals, underwriting details, and intended use of proceeds. The document is lengthy (15,000 characters) and contains substantive financial and operational data related to the bond issuance. It is not a brief announcement or a certification letter but a comprehensive disclosure document for a capital raising event. Therefore, it fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as bond issuances.
2018-04-16 Chinese
关于公司2018年面向合格投资者公开发行公司债券的更名公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the renaming of a corporate bond issuance by 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.). It details the approval by the China Securities Regulatory Commission, the issuance schedule, and the legal documents related to the bond issuance. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a formal notice about a change in the name of a bond issuance, which falls under updates related to capital or financing activities. The document length is short (1259 characters), and it is not a full report but an announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-04-16 Chinese
2018年面向合格投资者公开发行公司债券（第一期）信用评级报告
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data over multiple years, including assets, liabilities, revenues, and profits, as well as extensive industry analysis, company background, bond issuance details, and regulatory approvals. It discusses the company's business operations, market position, industry environment, and regulatory framework. The length is substantial (15,000 characters), and the content is comprehensive, including financial statements and management discussion. There is no indication that this is merely an announcement or a certification. The document resembles a comprehensive annual or periodic financial and business report. Given the detailed financial data and analysis for multiple years and the inclusion of bond issuance information, it aligns best with an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K) because the latest data is up to September 2017 (not a full fiscal year). Therefore, the document is classified as an Interim / Quarterly Report (IR). 9M 2017
2018-04-16 Chinese
2018年面向合格投资者公开发行公司债券（第一期）募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to "Offering Circular" or "Prospectus" for a corporate bond issuance by 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.) in 2018. It contains detailed information about the bond issuance, including legal compliance, risk factors, credit ratings, financial data, management discussion, and use of proceeds. The document is lengthy (15,000 characters) and includes comprehensive financial and operational details related to the bond issuance. This type of document is a detailed disclosure related to capital raising through bond issuance, which fits the category of Capital/Financing Update (CAP). It is not an annual report, audit report, or earnings release, nor is it a regulatory announcement or a proxy statement. Therefore, the most appropriate classification is CAP.
2018-04-16 Chinese
2018年面向合格投资者公开发行公司债券（第一期）发行公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of corporate bonds by 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.) in 2018. It includes extensive information about the bond issuance scale, terms, interest rates, issuance procedures, investor qualifications, underwriting, risk disclosures, and regulatory approvals. The document is titled as an "发行公告" (Issuance Announcement) and contains no financial statements or management discussion of financial results. It is not a full financial report but rather a capital market update about a financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance terms, consistent with a CAP filing rather than a brief announcement or a regulatory filing. Confidence is high due to the clear focus on bond issuance details and regulatory compliance for a financing event.
2018-04-16 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.